Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 165  

 
   Table of Contents      
INTERESTING CASES
Year : 2020  |  Volume : 19  |  Issue : 4  |  Page : 455-456

18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection


1 Department of Nuclear Medicine with PET-Center, Klinik Ottakring, Vienna, Austria
2 Department for Infectious Diseases and Tropical Medicine, Klinik Favoriten (KFJ), Vienna, Austria

Date of Submission04-Aug-2020
Date of Decision08-Aug-2020
Date of Acceptance23-Aug-2020
Date of Web Publication02-Oct-2020

Correspondence Address:
Prof. Siroos Mirzaei
Department of Nuclear Medicine with PET-Center, Klinik Ottakring (Wilhelminenspital), Montleartstr. 37, A-1160, Vienna
Austria
Login to access the Email id


DOI: 10.4103/wjnm.WJNM_110_20

Rights and Permissions
   Abstract 

The COVID-19 pandemic has now reached most countries. However, the referred patients to a nuclear medicine department will be primarily the asymptomatic ones. We report the case of a patient (84-year-old male) who was sent for18F-prostate-specific membrane antigen positron emission tomography computed tomography (PSMA PET-CT) with suspicion of recurrent disease after prostate cancer and total prostatectomy 2 years prior to the examination. He suffered from COVID-19 pneumonia 4 weeks prior to PET-CT examination. The18F-PSMA PET-CT revealed moderate elevated uptake in the area of previous pneumonia in the right lung. The radiological findings showed ground glass changes in this area indicating possible residual inflammatory disease even weeks after infection.

Keywords: 18F-prostate-specific membrane antigen, COVID-19, infection, positron emission tomography computed tomography, prostate cancer


How to cite this article:
Mirzaei S, Farhan C, Karolyi M. 18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection. World J Nucl Med 2020;19:455-6

How to cite this URL:
Mirzaei S, Farhan C, Karolyi M. 18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection. World J Nucl Med [serial online] 2020 [cited 2021 Jan 21];19:455-6. Available from: http://www.wjnm.org/text.asp?2020/19/4/455/297094


   Introduction Top


The COVID-19 pandemic has now reached most countries. Emergency room and intensive care staff are at increased risk for infection, however, the referred patients to a nuclear medicine department will be primarily the asymptomatic ones. Therefore, good communication with referral physicians and safety measures are mandatory for the protection of other patients and staff.[1],[2]

In a recent publication, it was suggested that18F-fluorodeoxyglucose positron emission tomography computed tomography (PET-CT) can identify COVID-19 cases in the absence or before symptom onset and may guide patient management.[3]


   Case Report Top


We report the case of a patient (84-year-old male) who was sent for 18F-prostate-specific membrane antigen (PSMA) PET-CT with suspicion of recurrent disease after prostate cancer and total prostatectomy 2 years prior to the examination. The patient suffered from COVID-19 pneumonia 4 weeks prior to PET-CT examination.

The examination was performed as elsewhere described.[4] Briefly, PET-CT images were performed 1 h after intravenous injection of 248 MBq18F-PSMA on a PET-CT scanner (Siemens Healthineers, Erlangen) and the images were analyzed on a Syngovia Workstation (Siemens Healthineers, Erlangen). The18F-PSMA PET-CT revealed moderate elevated uptake in the area of previous pneumonia as shown in [Figure 1]. The patient had no respiratory symptoms and no other signs of infection at the time of PET examination. The radiological findings showed ground glass changes in this area. These pulmonary findings were interpreted as remaining inflammatory changes in an already recovered patient after Covid-19 infection, as it has been ascribed to PSMA uptake in inflammation elsewhere.[5]
Figure 1: 18F-prostate-specific membrane antigen positron emission tomography computed tomography (84y, male) displays a diffuse moderate uptake in the right lung (SUVmax 2.6), in topographic correlation to ground glass opacities consistent with residual inflammation (black arrows), 4 weeks after COVID-19 infection

Click here to view



   Conclusion Top


To the best of our knowledge, this is the first case report with a pathological pulmonary uptake of a PSMA ligand with PET-CT in COVID-19 patients, indicating possible residual inflammatory disease even weeks after infection.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Czernin J, Fanti S, Meyer PT, Allen-Auerbach M, Hacker M, Sathekge M, et al. Imaging clinic operations in the times of COVID-19: Strategies, Precautions and Experiences. J Nucl Med 2020;47:2038-9..  Back to cited text no. 1
    
2.
Paez D, Gnanasegaran G, Fanti S, Bomanji J, Hacker M, Sathekge M, et al. COVID-19 pandemic: Guidance for nuclear medicine departments. Eur J Nucl Med Mol Imaging 2020;47:1615-9.  Back to cited text no. 2
    
3.
Setti L, Kirienko M, Dalto SC, Bonacina M, Bombardieri E. FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients. Eur J Nucl Med Mol Imaging 2020;47:1649-56.  Back to cited text no. 3
    
4.
Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, et al. (64) Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: First in-human studies. Cancer Biother Radiopharm 2016;31:277-86.  Back to cited text no. 4
    
5.
Sharif-Paghaleh E, Yap ML, Puh SL, Adam Badar A, Torres JB, Chuamsaamarkkee K, Kampmeier F, et al. Non-invasive whole-body detection of complement activation using radionuclide imaging in a mouse model of myocardial ischaemia-reperfusion injury. Sci Rep 2018;8:4687.  Back to cited text no. 5
    


    Figures

  [Figure 1]



 

Top
 
 
  Search
 
    Similar in PUBMED
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Conclusion
    References
    Article Figures

 Article Access Statistics
    Viewed204    
    Printed11    
    Emailed0    
    PDF Downloaded25    
    Comments [Add]    

Recommend this journal